Experts: EU Will Continue to Beat US on Biosimilar Adoption

As biologics research and development becomes more granular, biosimilars may wind up both less useful and profitable than boosters of the drug category once thought. According to experts, the first wave of biologic patent expiry is almost over — and a new set of expirations starting in 2024 will determine whether biosimilars will have as big an impact in the U.S. as they have in the European Union.

There has been a large number of biosimilar approvals in recent years, according to business intelligence firm GlobalData. The EU “experienced this biosimilar wave ahead of regions such as the US and Asia-Pacific because the EU created the first biosimilar-specific approval pathway,” according to Quentin Horgan, GlobalData’s senior drugs database analyst. Approvals of biosimilars have slowed down in recent years.

© 2021 MMIT

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured-Image-radar-on-drug-benefits-Pharma-Industry-Braces-as-Dems-Hash-Out-Drug-Price-Package.jpg
September 23

Pharma Industry Braces as Dems Hash Out Drug Price Package

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured-Image-radar-on-drug-benefits-Study-Flags-Potential-Benefit-of-Targeted-Medication-Reviews.jpg
September 23

Study Flags Potential Benefit of Targeted Medication Reviews

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured-Image-radar-on-drug-benefits-New-Schizophrenia-Drug-Will-Likely-Have-Familiar-Coverage.jpg
September 23

New Schizophrenia Drug Will Likely Have Familiar Coverage

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today